LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | Lapatinib | 1.11 | uM | LJP6 | 3 | M21 | 72 | hr | 868 | 3447 | 3486 | 0.9887 | 0.9850 |
| MDA-MB-231 | LDN-193189 | 1.11 | uM | LJP5 | 1 | G03 | 72 | hr | 868 | 2370 | 3486 | 0.6798 | 0.5736 |
| MDA-MB-231 | LDN-193189 | 1.11 | uM | LJP5 | 2 | G03 | 72 | hr | 868 | 2401 | 3486 | 0.6887 | 0.5855 |
| MDA-MB-231 | LDN-193189 | 1.11 | uM | LJP5 | 3 | G03 | 72 | hr | 868 | 2881 | 3486 | 0.8264 | 0.7688 |
| MDA-MB-231 | Linifanib | 1.11 | uM | LJP6 | 1 | J09 | 72 | hr | 868 | 3559 | 3486 | 1.0208 | 1.0277 |
| MDA-MB-231 | Linifanib | 1.11 | uM | LJP6 | 2 | J09 | 72 | hr | 868 | 3850 | 3486 | 1.1043 | 1.1389 |
| MDA-MB-231 | Linifanib | 1.11 | uM | LJP6 | 3 | J09 | 72 | hr | 868 | 4204 | 3486 | 1.2058 | 1.2741 |
| MDA-MB-231 | Linsitinib | 1.11 | uM | LJP5 | 1 | O21 | 72 | hr | 868 | 2576 | 3486 | 0.7389 | 0.6523 |
| MDA-MB-231 | Linsitinib | 1.11 | uM | LJP5 | 2 | O21 | 72 | hr | 868 | 3299 | 3486 | 0.9463 | 0.9284 |
| MDA-MB-231 | Linsitinib | 1.11 | uM | LJP5 | 3 | O21 | 72 | hr | 868 | 3060 | 3486 | 0.8777 | 0.8372 |
| MDA-MB-231 | Mitoxantrone | 1.11 | uM | LJP5 | 1 | C21 | 72 | hr | 868 | 641 | 3486 | 0.1839 | -0.0867 |
| MDA-MB-231 | Mitoxantrone | 1.11 | uM | LJP5 | 2 | C21 | 72 | hr | 868 | 807 | 3486 | 0.2315 | -0.0233 |
| MDA-MB-231 | Mitoxantrone | 1.11 | uM | LJP5 | 3 | C21 | 72 | hr | 868 | 706 | 3486 | 0.2025 | -0.0619 |
| MDA-MB-231 | Mitoxantrone | 1.11 | uM | LJP6 | 1 | C21 | 72 | hr | 868 | 744 | 3486 | 0.2134 | -0.0474 |
| MDA-MB-231 | Mitoxantrone | 1.11 | uM | LJP6 | 2 | C21 | 72 | hr | 868 | 718 | 3486 | 0.2059 | -0.0573 |
| MDA-MB-231 | Mitoxantrone | 1.11 | uM | LJP6 | 3 | C21 | 72 | hr | 868 | 694 | 3486 | 0.1991 | -0.0665 |
| MDA-MB-231 | MK2206 | 1.11 | uM | LJP6 | 1 | F03 | 72 | hr | 868 | 2625 | 3486 | 0.7529 | 0.6710 |
| MDA-MB-231 | MK2206 | 1.11 | uM | LJP6 | 2 | F03 | 72 | hr | 868 | 2772 | 3486 | 0.7951 | 0.7272 |
| MDA-MB-231 | MK2206 | 1.11 | uM | LJP6 | 3 | F03 | 72 | hr | 868 | 2633 | 3486 | 0.7552 | 0.6741 |
| MDA-MB-231 | Neratinib | 1.11 | uM | LJP5 | 1 | A15 | 72 | hr | 868 | 1847 | 3486 | 0.5298 | 0.3739 |
| MDA-MB-231 | Neratinib | 1.11 | uM | LJP5 | 2 | A15 | 72 | hr | 868 | 1734 | 3486 | 0.4974 | 0.3307 |
| MDA-MB-231 | Neratinib | 1.11 | uM | LJP5 | 3 | A15 | 72 | hr | 868 | 2131 | 3486 | 0.6112 | 0.4823 |
| MDA-MB-231 | Nilotinib | 1.11 | uM | LJP5 | 1 | N15 | 72 | hr | 868 | 2077 | 3486 | 0.5957 | 0.4617 |
| MDA-MB-231 | Nilotinib | 1.11 | uM | LJP5 | 2 | N15 | 72 | hr | 868 | 2656 | 3486 | 0.7618 | 0.6829 |
| MDA-MB-231 | Nilotinib | 1.11 | uM | LJP5 | 3 | N15 | 72 | hr | 868 | 2210 | 3486 | 0.6339 | 0.5125 |